3YEH CC, LIAO CC, CHANG YC, et al. Adverse Outcomes Af- ter Noncardiac Surgery in Patients With Diabetes A nationwide population-based retrospective cohort study [J]. Diabetes Care, 2013,36 (10) : 3216-3221.
4CHANDEL NS, BUDINGER GR. The cellular basis for diverse responses to oxygen [J]. Free Radic Biol Med, 2007,42(2): 165-174.
5PILLAI R, HUYPENS P, HUANG M, et al. Aryl hydrocarbonreceptor nuclear translocator/hypoxia-inducible factor-1 {betal plays a critical role in maintaining glucose-stimulated anaplerosis and insulin release from pancreatic {betat-cells [J]. Biol Chem, 2011, 286(2) : 1014-1024.
6SEMENZA GL. HIF-1 mediates metabolic responses to intratu- moral hypoxia and oncogenic mutations [J]. Clin Invest, 2013, 123(9) :3664-3671.
7GREGG L SEMENZA. HIF-1 and mechanisms of hypoxia sens- ing [J]. Curr Opin Cell Biol, 2001,13(2) : 167-171.
8SATO T, TANNO M, MIKI T, et al. Erythropoietin (EPO) af- fords more potent cardioprotection by activation of distinct signal- ing to mitochondrial kinases compared with carbamylated EPO [J]. Cardiovasc Drugs Ther, 2010,24(5-6) :401-408.
9HEATHER LC, CLARKE K. Metabolism, hypoxia and the dia- betic heart [J]. Mol Cell Cardiol, 2011,50(4) :598-605.
10XIAO H, GU Z, WANG G, et al. The possible mechanisms un- derlying the impairment of HIF-lc pathway signaling in hyper- glycemia and the beneficial effects of certain therapies [J]. Int J Med Sci, 2013,10(10) : 1412-1421.
